JP2013511287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511287A5 JP2013511287A5 JP2012540160A JP2012540160A JP2013511287A5 JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5 JP 2012540160 A JP2012540160 A JP 2012540160A JP 2012540160 A JP2012540160 A JP 2012540160A JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- diabetes
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 206010033307 Overweight Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000283080 Proboscidea <mammal> Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 230000030135 gastric motility Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26375209P | 2009-11-23 | 2009-11-23 | |
| US61/263,752 | 2009-11-23 | ||
| PCT/US2010/057890 WO2011063414A1 (en) | 2009-11-23 | 2010-11-23 | Polypeptide conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511287A JP2013511287A (ja) | 2013-04-04 |
| JP2013511287A5 true JP2013511287A5 (enExample) | 2013-11-14 |
Family
ID=44060086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540160A Pending JP2013511287A (ja) | 2009-11-23 | 2010-11-23 | ポリペプチド・コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140066370A1 (enExample) |
| EP (1) | EP2504021A4 (enExample) |
| JP (1) | JP2013511287A (enExample) |
| KR (1) | KR20120116942A (enExample) |
| CN (1) | CN102781458A (enExample) |
| AU (1) | AU2010321587A1 (enExample) |
| CA (1) | CA2781672A1 (enExample) |
| IL (1) | IL219948A0 (enExample) |
| MX (1) | MX2012005912A (enExample) |
| RU (1) | RU2012126101A (enExample) |
| WO (1) | WO2011063414A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104945499B (zh) * | 2014-03-31 | 2019-12-10 | 博瑞生物医药（苏州）股份有限公司 | 结构修饰的glp-1类似物及其制备方法 |
| TWI772252B (zh) * | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN106554404B (zh) * | 2015-09-25 | 2020-11-20 | 博瑞生物医药（苏州）股份有限公司 | 艾塞那肽修饰物及其用途 |
| JP7751603B2 (ja) * | 2020-07-02 | 2025-10-08 | サノフイ | 低減された活性を有するｇｌｐ－１ｒアゴニストペプチド |
| TWI850611B (zh) * | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| DE69921102T2 (de) | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
| KR20070051948A (ko) | 1999-01-14 | 2007-05-18 | 아밀린 파마슈티칼스, 인크. | 글루카곤 억제용 제약학적 조성물 |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| SI1180121T1 (en) | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
| AU2005320351B2 (en) | 2004-02-11 | 2010-06-03 | Amylin Pharmaceuticals, Llc | Amylin family peptides and methods for making and using them |
| RU2378285C2 (ru) | 2004-02-11 | 2010-01-10 | Амилин Фармасьютикалз, Инк. | Гибридные полипептиды с селектируемыми свойствами |
| US7465234B2 (en) * | 2004-09-13 | 2008-12-16 | The Boeing Company | Hybrid fastening system and associated method of fastening |
| AU2006213607A1 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
| AU2006279680B2 (en) * | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| KR101399178B1 (ko) * | 2005-08-11 | 2014-06-18 | 아스트라제네카 파마수티컬스 엘피 | 선별가능한 특성을 갖는 하이브리드 폴리펩티드 |
| WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
| US20070238669A1 (en) | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
| JP2009538824A (ja) | 2006-03-31 | 2009-11-12 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 精神疾患及び障害治療用アミリン及びアミリンアゴニスト |
| US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| EP2636680A3 (en) | 2006-05-26 | 2013-12-11 | Amylin Pharmaceuticals, LLC | Composition and methods for treatment of congestive heart failure |
| CN102827284B (zh) | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| WO2010118384A2 (en) * | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| WO2012036962A2 (en) * | 2010-09-13 | 2012-03-22 | Amylin Pharmaceuticals, Inc. | C-terminal amidation of polypeptides |
| US10755005B1 (en) | 2015-12-31 | 2020-08-25 | Dassault Systemes Solidworks Corporation | Providing a single command to create multiple CAD features |
-
2010
- 2010-11-23 KR KR1020127016229A patent/KR20120116942A/ko not_active Withdrawn
- 2010-11-23 US US13/511,201 patent/US20140066370A1/en not_active Abandoned
- 2010-11-23 AU AU2010321587A patent/AU2010321587A1/en not_active Abandoned
- 2010-11-23 WO PCT/US2010/057890 patent/WO2011063414A1/en not_active Ceased
- 2010-11-23 MX MX2012005912A patent/MX2012005912A/es not_active Application Discontinuation
- 2010-11-23 JP JP2012540160A patent/JP2013511287A/ja active Pending
- 2010-11-23 RU RU2012126101/10A patent/RU2012126101A/ru not_active Application Discontinuation
- 2010-11-23 CA CA2781672A patent/CA2781672A1/en not_active Abandoned
- 2010-11-23 CN CN2010800621149A patent/CN102781458A/zh active Pending
- 2010-11-23 EP EP10832376.7A patent/EP2504021A4/en not_active Withdrawn
-
2012
- 2012-05-23 IL IL219948A patent/IL219948A0/en unknown